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Abstract 
 
Since the 1990s, glycated haemoglobin (HbA1C) has been the gold standard for monitoring 
glycaemic control in people diagnosed as having either type 1 diabetes mellitus (T1DM) or type 2 
diabetes mellitus (T2DM). Discussions are underway about diagnosing diabetes mellitus on the basis 
of HbA1C titres and using HbA1C tests to screen for T2DM. These discussions have focused on the 
relative benefits for individual patients, with some attention directed towards reduced costs to 
healthcare systems and benefits to society. We argue that there are strong ethical reasons for 
adopting HbA1C-based diagnosis and T2DM screening that have not yet been articulated. The 
rationale includes the differential impact of HbA1C-based diabetic testing on disadvantaged groups, 
and what we are beginning to learn about HbA1C vis-à-vis population health. Although it is arguable 
that screening must primarily benefit the individual, using HbA1C to diagnose and screen for T2DM 
may promote a more just distribution of health resources and lead to advances in investigating, 
monitoring and tackling the social determinants of health. 
 
 
Introduction 
 
The rising incidence of type 2 diabetes mellitus (T2DM) is a pressing global health concern. The need 
to identify individuals at elevated risk of diabetic complications more reliably and earlier has 
prompted discussions as to the costs and benefits of changing the diagnostic criteria from a glucose-
based measure to glycated haemoglobin (HbA1C) (box 1), with a suggested threshold for diabetes of 
6.5% HbA1C.1 While HbA1C measures could also be used to confirm type 1 diabetes mellitus 
(T1DM), since T1DM usually presents acutely, the practical and ethical issues associated with HbA1C-
based diagnosis apply chiefly to T2DM. The primary advantage of HbA1C-based tests is that they 
measure an individual's exposure to hyperglycaemic states over a period of weeks, rather than 
hours, which can facilitate the identification of low levels of persistent hyperglycaemia. The other 
key reason to change diagnostic techniques for diabetes is the stable relationship between an 
individual's HbA1C titres and their risk of macrovascular disease. Currently, fasting plasma glucose 
levels (FPG) for diagnosing diabetes are set at 7.0 mmol/l because there is a sharp inflexion at this 
point for the risk of microvascular disease (renal, vision, etc.). It has not, however, been possible to 
set a diagnostic criterion based on FPG to reflect risk of macrovascular disease, because an 
individual's risk of cardiovascular pathologies rises gradually relative to FPG. Consequently, current 
methods of diagnosing diabetes do little to mitigate the risks of macrovascular diseases in individual 
cases.2 When examined from both primary care and population health perspectives, the lag 
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between onset of cellular dysfunction and glucose-based clinical diagnosis (estimated at 7 years, on 
average) is now thought to have a major impact on prognoses for patients with T2DM. Because 
HbA1C levels can be used to predict both microvascular disease and the risks of fatal and non-fatal 
macrovascular events in pre-diabetic and diagnosed cases of T2DM, the American Diabetic 
Association has recently recommended that HbA1C levels should be used to define and diagnose 
diabetic diseases.1 
 
Box 1: Glycated haemoglobin (HbA1C), diabetes mellitus, cardiovascular disease and population 
health 
 
HbA1C is a blood-borne glycoprotein that forms through a direct reaction between plasma glucose 
and haemoglobin. Foundational trials conducted in the 1990s established HbA1C assays as a reliable 
index of glycaemic control in individuals with diabetes.3 4 More recent population-based studies 
confirm that HbA1C is also a reliable marker of cardiovascular risk in both non-diabetic and diabetic 
populations, although the causal role of glucose in cardiovascular disease is as yet unclear.5 Social 
epidemiologists have used HbA1C as a biological measure to compare with self-rated health. Studies 
have consistently found raised HbA1C levels associated with increased exposure to stressors in non-
diabetic individuals and that there is an inverse and independent relationship between raised HbA1C 
and socioeconomic status and social disadvantage.6 7 Hence HbA1C is a stable biomarker of an 
individual's exposure to hyperglycaemic states and cardiometabolic risks, even in patients without 
measurable abnormalities in glucose metabolism or who are below the threshold for clinical T2DM. 
The move to HbA1C-based diagnosis is pragmatic. The aim is to identify at-risk individuals earlier, 
well before they have clinically evident glucose dysregulation and an elevated risk of diabetic 
complications. 
 
 
Current practices and debates surrounding T2DM screening, diagnosis and prevention 
 
Diagnosis and screening are distinct types of clinical practice. Diagnosis is a process of identifying 
potential abnormalities in an affected individual seeking healthcare, whereas screening is used to 
identify members of a population who have a specific condition, or are at heightened risk of 
developing it, but who are not specifically seeking treatment. Diagnosis generally presupposes some 
form of intervention, whereas screening may focus the attention of individuals, care providers and 
policy makers on preventive actions. Clinical screening for T2DM has generally only been undertaken 
on an ad hoc and opportunistic basis in most developed nations. As evidence continues to emerge 
that earlier diagnosis and treatment of hyperglycaemia and related metabolic abnormalities is 
beneficial,8 9 a growing number of professional organisations are advocating targeted screening for 
T2DM in high-risk populations.10 Past attempts to screen for these conditions have been haphazard, 
relied on a variety of different tests and cut-offs, and have had variable success. Although the utility 
of population-level screening for T2DM remains controversial, the emerging consensus is that 
HbA1C may be a better screening tool than the alternatives.11 12 Systematic use of HbA1C assays 
may prove to be a powerful secondary prevention measure, as the earlier identification of at-risk 
and pre-diabetic individuals provides those affected and their primary care providers with a better 
chance of avoiding the onset, risks and burdens of diabetic complications (assuming that relevant 
services are available). 
 
Past reluctance to adopt HbA1C as a diagnostic criterion for T2DM reflected legitimate concerns 
about technological standardisation, which have now been met. Like any test, HbA1C assays have 
limitations, but in terms of stability, accuracy and precision, they are now considered the equal of 
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standard glucose-based testing protocols.1 13 As well as providing a longitudinal measure of 
hyperglycaemia and macrovascular risks, there are practical advantages to HbA1C testing. HbA1C 
testing procedures are convenient. They do not require the patient to fast, and the assay can readily 
be bundled with other tests, unlike oral glucose tolerance tests (OGTT) and FPG measurements. 
HbA1C is an accurate test for hyperglycaemia and can be easily and immediately administered in 
primary care settings. In contrast, FPG and OGTTs are intrusive, can be difficult to interpret, and rely 
on high levels of patient compliance. FPG and OGTT also result in substantial under-diagnosis; 
epidemiological surveys consistently estimate this to be as high as 30–50% of all cases.11 
 
HbA1C and social epidemiology 
 
As well as being a direct measure of glycaemic levels, HbA1C titres have been used as a measure of 
population health unrelated to T2DM screening. Such research sought to investigate social 
inequalities in disease prevalence and outcomes associated with social gradients, which were 
otherwise unexplained by classic behavioural dimensions of health risk exposure. Social 
epidemiologists used HbA1C as a biomarker to compare with individuals' self-rated health, reflecting 
relative intensity and health effects of the social environment and psychosocial stress in populations 
and subpopulations. Studies have consistently found raised HbA1C levels associated with increased 
exposure to stressors in non-diabetic individuals, and identified an inverse and independent 
relationship between raised HbA1C and socioeconomic status and social disadvantage.6 7 Because 
of this association, aggregated databases of HbA1C stand to provide population risk measures, and 
vital insights into how the health of entire populations is influenced by social determinants, including 
emotional well-being, social networks and characteristics of where people live. The potential to use 
a biological measure such as HbA1C to assess the relative health and exposure to stressors in 
different populations has important implications in health policy formation and for the allocation of 
scarce resources. 
 
Ethical grounds for adopting HbA1C as the diagnostic screening test for T2DM 
 
While the evidentiary and practical advantages of using HbA1C as a diagnostic screen for T2DM and 
as a measure of population health are matters for careful and considered discussion, we argue that 
the test has ethical advantages over existing clinical practices. These advantages occur for individuals 
in primary care settings, and at the level of research, planning and intervention to improve the 
overall health of populations (Box 2). 
 
Box 2: A case study 
 
The value of these kinds of data is illustrated by recent research conducted with black military 
veterans living with T2DM in Philadelphia, USA. The findings from this research showed that patients 
who perceived their neighbourhoods as places where people work together for improvements 
tended to have lower HbA1C scores than those who did not perceive their neighbourhoods in this 
way.32 As perceptions of neighbourhoods are modifiable, this study suggests that interventions 
aimed at improving perceptions by fostering experiences of community inclusion and social support 
could prove to be important for preventing the onset of T2DM, as well as of related health problems. 
 
Screening and diagnosis in primary care 
 
Screening a population for a disease is not necessarily a benign activity; it can cause harms as well as 
provide benefits. Aside from the risks of false positives and unnecessary interventions, the mere 
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invitation to undergo a medical procedure can change people's image of themselves, thereby 
challenging and even violating their personal integrity.14 There is some ethical consensus around 
the view that the benefits of a screening programme must accrue to those individuals who take part, 
rather than to third parties. Participation in a screening programme should reflect an autonomous 
choice, informed by a clear understanding of the possible individual benefits and harms.15 Recent 
research has largely allayed concerns that informed consent deters participation, or causes 
unnecessary anxiety or an unwarranted sense of insecurity for those who choose to be screened.16 
17 In relation to screening for T2DM, early detection seems to be beneficial for the individual, 
especially if microvascular risks, macrovascular risks and metabolic abnormalities can be mitigated 
by lifestyle changes. Thus the potential harms of offering screening for T2DM to a targeted 
population appear to be outweighed by the benefits. Notwithstanding the limits of autonomous 
choice as an ethical framework,18 there remains ethical concern about how best to provide 
disadvantaged and ‘at-risk’ groups access to screening programmes.19 20 
 
HbA1C-based screening may be superior to glucose tests for addressing this concern. The test is 
more convenient for the patient and far simpler to understand than the complicated protocols and 
confusing classifications that surround glucose-based tests and diagnostic categories. This leads to 
two consequences. First, as the costs and benefits of diabetes screening with HbA1C are more easily 
explained to individual patients than are the alternatives (i.e., FPG and OGTT protocols), there is an 
increased likelihood that those being tested will give valid informed consent for screening 
procedures. Second, HbA1C, as a simpler testing regimen than the alternatives, has the potential to 
make diagnostic procedures—whether it is a screen for an asymptomatic individual or a test to 
confirm the T2DM diagnosis—more accessible to socially disadvantaged groups and to those unable 
to comply readily with complicated test regimens.16 HbA1C assays facilitate opportunistic screening, 
thereby avoiding a loss to follow-up of those who do not return for confirmatory diagnostic tests (as 
is required for FPG and OGTT protocols), but who would be willing and able to fill a prescription, to 
modify their diets, or to become more physically active based on diagnostic test results delivered in 
a timely fashion. Moreover, even when individuals do not benefit from continuity of care or from 
medical technologies such as pharmaceuticals to lower blood sugar levels, diagnostic and screening 
data derived can enable population surveillance and related interventions (eg, improving access to 
healthcare among disadvantaged social groups). 
 
Adopting HbA1C as the diagnostic criterion for diabetes may promote a better balance between the 
core values and principles that underpin current conceptions of ethical clinical practice. Early 
identification of those at risk provides scope for the timely formation of interpersonal provider–
patient relationships, attention to social processes, and concern for life plans. All these features are 
now considered to be central to effective, efficacious and respectful care of people with long-term 
conditions.21 22 HbA1C screening may more easily meet the requirements of non-maleficence and 
beneficence compared with alternatives, as more accurate testing and earlier diagnosis is likely to 
promote more favourable outcomes for high-risk individuals. The only caveat to this claim is that the 
lifestyle risks that promote T2DM must be modifiable. If it turns out that disadvantaged individuals 
are unable to address the drivers of macrovascular diseases, then the increasing incidence of these 
conditions among these groups could serve to highlight the need for structural reforms and 
population-level interventions. 
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Extending diabetic research to disadvantaged populations 
Another potential ethical benefit of HbA1C screening is that it may promote greater justice in 
research by facilitating the inclusion of socially disadvantaged groups in evaluating the effectiveness 
of approaches to diabetic management relevant to their situations. 
 
Disadvantaged groups are at highest risk for incidence of T2DM, for related complications, and for 
comorbidities. Members of these groups often have low health literacy, experience low levels of 
provider access, face significant psychosocial stressors, and struggle to manage the extra burdens 
imposed by diabetes treatment.23 These groups are far less likely to have access to appropriate and 
effective interventions for pre-diabetes and T2DM,24 and generally less likely to participate in and 
benefit from relevant T2DM research, which currently focuses on pharmacological interventions and 
modifying the behavioural patterns of individual patients. While emerging evidence indicates that 
earlier intervention can provide for sustained prevention of T2DM,25 the challenge is to translate 
these findings to the ‘real’ world.26 To the extent that lifestyle risks are modifiable, then there is a 
strong likelihood that disadvantaged populations would disproportionately benefit, and do better 
with earlier diagnosis. 
 
Yet the research evidence that informs these types of individually focused clinical interventions may 
not reflect the circumstances and needs of disadvantaged groups. This kind of mismatch can occur 
through a lack of representation in research design, and through exclusion criteria such as presence 
of comorbidities and participant availability, leading to a lack of evidence that is applicable to those 
excluded from studies. Given the importance of research evidence in informing resource allocation 
decisions and policy development, the lack of evidence as to effectiveness in disadvantaged 
populations is a serious issue that compromises access to care and health equity.27 Using HbA1C as 
a research tool could facilitate the inclusion of disadvantaged groups in relevant studies, thereby 
avoiding these potential harms. Moreover, it is likely that making these services accessible to those 
who need them most will benefit the whole of society, through development of more equitable 
service models and lower rates of morbidity and mortality.28 
 
Beyond their facility as a tool to evaluate interventions in primary care settings and members of 
hard-to-reach populations, HbA1C titres are also a useful gauge of population health, including the 
effects of exposure to environmental stressors. Modest increases in the level of HbA1C have been 
correlated with key measures of socioeconomic status and job stress,6 potentially contributing to 
increased risk of heart disease and other morbidities in non-diabetic populations. The systematic 
collection of HbA1C information to create population health databases has potential for opening up 
new ways of investigating the complex pathways through which socioeconomic and structural 
factors impact on health. Although our understanding of the mechanisms through which social 
environments affect health remains limited and partial, the available evidence suggests that social 
relationships and social dimensions of environments may have significant effects on the success or 
failure of attempts to address burdens of chronic disease in diabetic and non-diabetic individuals. 
The link between HbA1C levels and macrovascular risks is potentially of great significance because 
most people with diabetes, and many without diabetes, will die from macrovascular disease.5 At the 
same time, microvascular risks such as vision loss and kidney failure are often dreaded more than 
macrovascular risks by individuals with diabetes.29 Elevated HbA1C levels correlate with both 
macrovascular and microvascular risks, and also appear to have value vis-à-vis measuring the impact 
of exposure to stressors. For these reasons, using HbA1C to diagnose and screen for T2DM could 
effectively address the ethical tensions between population- and individual-level priorities in 
screening. 
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If HbA1C proves to be a reliable research tool investigating the links between health and the social, 
economic and cultural circumstances of disadvantage, there are potential benefits, including novel 
intervention methods and increased opportunities for understanding and addressing the effects of 
disadvantage on health. The creation of population health databases of HbA1C could further these 
aims.30 For example, a population map identifying areas of raised HbA1C could inform social 
interventions, again with greatest benefit to the worst-off.31 HbA1C-based testing may provide a 
greater differential benefit for disadvantaged groups through a timelier diagnosis of insulin 
intolerance; in addition, because HbA1C also reflects the effects of other macrovascular risk factors, 
the systematic collection of these data may have a differential impact on the prioritisation of health 
outcomes at the level of populations. If this then leads to the greatest benefits accruing to the most 
disadvantaged, it is possible that HbA1C may promote greater justice in healthcare. 
 
The case for Hb1AC testing and evidence-based social medicine 
 
Thirty years ago, Geoffrey Rose argued that medicine has a duty of care not only to individual 
patients but also to the communities and populations to which we all belong.33 Social relationships 
and environments appear to exert direct influences on major causes of mortality, including from 
cardiovascular disease.34 Therefore, non-medical determinants of population health deserve our 
attention when discussing the relative merits of diagnostic tests for T2DM. While we must ensure 
that targeted individuals are the beneficiaries of screening programmes, not all of these benefits 
need be direct. We should also consider the potential for benefits to the health of populations, as, 
after all, individuals stand to benefit from improvements in population health. 
 
Addressing the social determinants of health and the associated health gradient is a matter of 
justice; however, it is difficult for healthcare providers to address broader issues of justice, as their 
focus is on individual patients presenting for care. Nonetheless, HbA1C data may be suited to 
providing the type of evidence base and evaluative framework necessary to broaden the focus of 
macrovascular disease prevention and treatment interventions beyond clinical settings. 
 
With the routine availability of HbA1C administrative data derived from screening for T2DM as well 
as from monitoring people diagnosed with T2DM, it would be possible to measure longitudinally the 
overall population health impact of social interventions such as community development initiatives 
and to compare the cost-effectiveness of social interventions with pharmaceutical treatments. Given 
that the net impact of patient self-management on the health gradient is likely to be very small,35 
inequities in outcomes for T2DM and macrovascular disease are unlikely to lessen significantly, 
unless these new forms of evidence can be generated, evaluated and integrated into established 
systems.23 
 
Conclusion 
 
HbA1C-based testing for T2DM has significant practical and ethical benefits over existing diagnostic 
and screening protocols. HbA1C testing for T2DM should improve access to care for disadvantaged 
populations - who are at heightened risk of and over-represented among people with T2DM. Any 
step that leads to greater inclusion of these groups is likely to promote greater justice in healthcare 
provision, research and planning. At the same time, the wealth of data created from population-
level HbA1C screening also has the potential to allow us to better investigate, monitor and reduce 
the structurally embedded causes of population-level health inequities. 
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